




CJC/Ipamorelin

Sample vial 6, injection 1 | Client report THPN-CJCI-10-092126

Results and chromatograms
Lot # NXP-CJCI-002 | Client: NexPept

Laboratory Analysis: LAB-CA-02

Laboratory identity and applicable credentials are maintained by Testides and are available to regulatory authorities where required by law.


VIAL PHOTOGRAPH	SAMPLE INFORMATION	ANALYSIS	RUN DETAILS
	Peptide: CJC/Ipamorelin	Method: HPLC-UV	Run date: Sep 25, 2026
	Client ID: THPN-CJCI-10-092126	Channel: 214 nm	Acquired: 18:17:06 UTC
	Label claim: 10 mg	Integration: Laboratory	Run time: 25 min
	Injection: 10 uL, 214 nm	Identity: Conforms	Instrument: HPLC 01

RESULTS AT A GLANCE

PROJECTED AMOUNT 11.91 mg* SUM OF COMPONENTS; SOME EXTRAPOLATED	HPLC PURITY 99.77% NAMED COMPONENTS, 214 NM*	CONTENT VS. LABEL 119.1% 11.91 MG OF 10 MG CLAIMED	IDENTITY Conforms PEAK IDENTITY CONFIRMED**
CJC-1295 (NO DAC) 5.36 mg* 107.2% OF 5 MG LABEL; EXTRAPOLATED	IPAMORELIN 6.55 mg† 131.1% OF 5 MG LABEL, BY PEAK AREA		
ENDOTOXINS 1.0 EU/mL BELOW LIMIT (≤ 1 EU/ML)	HEAVY METALS Below reference limits USP <232> / ICH Q3D		

CHROMATOGRAM

As integrated by the laboratory - every plotted reading, with its baselines and peak marks



HPLC PURITY (214 NM)

Named components 99.77% Laboratory integration	Integrated peaks 4 Counted in the total	Smallest peak integrated 0.10% Of total area	Recovered chromatogram ±0.22% Area vs. laboratory table
---	--	---	--

Purity is the component peaks' share of the total peak area the laboratory integrated at 214 nm. The smallest peak it integrated was 0.10% of the total; the laboratory does not state a reporting threshold, so peaks below the ones it integrated are not counted. Integrating the chromatogram recovered from the laboratory's report reproduces its component area to within 0.22%. This result rests on a single injection.

The chromatogram is recovered point for point from the laboratory's report: 571 plotted readings from 10.50 to 20.00 min, joined as drawn; nothing is smoothed or resampled.

* HPLC purity is the component peaks' share of all peak area the laboratory integrated; every peak is itemised on page 3.

** Identity conforms. Retention time confirmed for CJC-1295 (no DAC) (its reference standard, -0.1%). Ipamorelin is identified by elution order; no reference on the sample's method.




CJC/lpamorelin

Sample vial 6, injection 1 | Client report THPN-CJCI-10-092126

Reference comparison and calculation

Lot # NXP-CJCI-002 | Client: NexPept

CONCENTRATION CALIBRATION - 214 NM (LABORATORY VALIDATION CURVES)





Ipamorelin

Estimated by peak area: the laboratory holds no curve for Ipamorelin.

Component	Peaks	Area %	mg/mL injected	Laboratory curve	Amount	Label share	Content
CJC-1295 (no DAC)	Peak#2	16.73%	0.5358 *	CJC, HPLC 01	5.36 mg	5 mg	107.2%
Ipamorelin	Peak#1	83.04%	0.6553	By peak area	6.55 mg	5 mg	131.1%

† The vial is reconstituted in 2 mL of diluent and diluted x5, which puts the component present in the smallest amount at the working 0.5 mg/mL. Label shares follow the blend's recorded composition: CJC-1295 (no DAC) 5 mg, Ipamorelin 5 mg. Total 11.91 mg. A component with no laboratory curve is estimated by peak area. * Outside the range of the laboratory's curve; the reading is extrapolated.

NAMED COMPONENT PEAKS



Native plotted readings with the laboratory's baselines and peak marks; nothing is smoothed or resampled.

Each component is confirmed by retention time against its reference where one is on the sample's method, otherwise by elution order; a component can show as more than one peak.

BACTERIAL ENDOTOXINS (USP <85>)

RESULT PASS NEGATIVE BY THE LABORATORY	THRESHOLD ≤ 1 EU/mL AT OR BELOW PASSES	METHOD Gel-clot LAL USP <85>	CONTROLS Passed POSITIVE AND NEGATIVE
---	---	---	--

At or below the 1 EU/mL threshold

The measured value, the gel-clot readings, the lysate, the controls and the calculation are on page 3.



CJC/lpamorelin

Sample vial 6, injection 1 | Client report THPN-CJCI-10-092126

Definitions, calculation detail, and scope

Lot # NXP-CJCI-002 | Client: NexPept

HOW TO READ THIS REPORT

Start with the result on page 1. Pages 2 and 3 show the curve, comparison, and peaks behind it.

01

Recovered chromatogram

The laboratory's trace, read back point for point from its report.

02

Integrated peak table

Every peak the laboratory integrated, and which one is the analyte.

03

Validation curve

Converts the peak area to a concentration for this analyte.

WHAT THE RECOVERED CHROMATOGRAM ADDS

How the chromatogram on this report was obtained

How it was recovered

The laboratory's data system draws the chromatogram in its report as vector data. Every vertex it drew was read back - 571 readings - and both axes were calibrated from the report's own tick marks. Integrating the recovered trace over the laboratory's baselines and peak marks reproduces the area in its peak table to within 0.22%.

What it can and cannot show

It shows every peak, shoulder and baseline the laboratory integrated, at the resolution the laboratory printed. It carries a single wavelength and no UV spectrum, so it cannot reveal a co-eluting compound the way diode-array data can.

Scope: the recovered chromatogram reproduces the laboratory's report. It does not re-measure the sample.

HOW THE PURITY RESULT WAS MEASURED

214 nm area percent, from the laboratory's own integration

The laboratory integrated each peak to its own baseline and named the analyte's peak in its processing method. Purity is that peak's share of the total integrated area; the shares below are recomputed from the areas, and each peak's area is checked against the recovered chromatogram.

$$\text{Purity (\%)} = \text{assigned peak area} / \text{total integrated peak area} \times 100$$

Peak	RT (min)	Area (uV*s)	Area %	Tailing	Plates	Role	Recovered
1	11.678	14,954,233	83.04	1.29	70,492	Peak#1 - Ipamorelin	14,921,419 (-0.22%)
2	12.109	18,156	0.10	1.00	56,408	impurity	-
3	12.559	23,949	0.13	1.00	17,381	impurity	-

and 1 further peak(s); the complete table is in the data package

Integrated peaks 4 | smallest 0.10% of total | injections 1

Area percent assumes every peak absorbs at 214 nm like the main peak; the analyte's peak is the one the laboratory's method names. Recovered areas are compared for the analyte's peaks of 1% or more.

BACTERIAL ENDOTOXINS — HOW THE RESULT WAS MEASURED

Measured: 1.0 EU/mL | laboratory result: Negative

Replicate	1/2	1/4	1/8	1/16	1/32	Endpoint
1	+	+	+	-	-	1/8
2	+	+	+	-	-	1/8

Each replicate at each two-fold dilution of the sample solution: + firm gel, - no gel

Lysate PYROGENT 125 Plus lot DC0423; labelled sensitivity $\lambda = 0.125$ EU/mL. Dilutions 1/2 to 1/32, two-fold, in 2 replicates. Endotoxin concentration = lysate sensitivity / mean endpoint = $0.125 \text{ EU/mL} / 1/8 = 1.0 \text{ EU/mL}$. The mean endpoint is the geometric mean of the replicates' endpoints (the most dilute tube that gelled).

Laboratory worksheet MC-02777, tested Sep 23, 2026, approved Sep 25, 2026. The positive control gelled and the negative control did not, as required.

HEAVY-METAL REFERENCE LIMITS

Arsenic, cadmium, lead and mercury are ICH Q3D Class 1 elemental impurities. The reference limits are the USP <232> / ICH Q3D permitted daily exposures for parenteral products, converted to a concentration assuming 10 g of product a day (Option 1). A typical peptide dose is a few milligrams, so these limits are very conservative. "Below reference limit" means the measured concentration is under that limit.

WHAT THIS REPORT CAN AND CANNOT TELL YOU

The report explains the measurement; it does not decide how a material should be used

Observed evidence

The laboratory's chromatogram, its integration, and its validation curve.

Calculated results

Area-percent purity, concentration, projected amount, and calibration trace.

Method context

Retention time against the reference standard or the report's other vials, where on the same method.

Safety and regulatory status

No conclusion on safety, efficacy, fitness for use, or regulatory status.

This analytical record does not authorize or endorse manufacture, sale, marketing, distribution, or use of the material.



CJC/lpamorelin

Sample vial 6, injection 1 | Client report THPN-CJCI-10-092126

Definitions, calculation detail, and scope

Lot # NXP-CJCI-002 | Client: NexPept

HEAVY METALS (USP <233>)

ARSENIC 0.003 ppm AS, REFERENCE LIMIT 1.5 PPM	CADMIUM 0.001 ppm CD, REFERENCE LIMIT 0.2 PPM	LEAD 0.001 ppm PB, REFERENCE LIMIT 0.5 PPM	MERCURY 0.001 ppm HG, REFERENCE LIMIT 0.3 PPM
--	--	---	--

Element	Symbol	Result	Reference limit	Status	Method
Arsenic	As	0.003 ppm	1.5 ppm	Below reference limit	USP <233>
Cadmium	Cd	0.001 ppm	0.2 ppm	Below reference limit	USP <233>
Lead	Pb	0.001 ppm	0.5 ppm	Below reference limit	USP <233>
Mercury	Hg	0.001 ppm	0.3 ppm	Below reference limit	USP <233>

Reference limits: USP <232> / ICH Q3D Class 1, parenteral, Option 1 (10 g/day).

Laboratory certificate AR-115067, received Sep 25, 2026, processed Oct 05, 2026, approved Oct 06, 2026. Specification: Report as found. The figures are in parts per million (ppm), as the laboratory reported them.

ABOUT THE TESTS

The heavy metals test measures the elemental impurities arsenic, cadmium, lead and mercury by the procedures of USP <233>. The laboratory reported each element in parts per million (ppm).

Arsenic, cadmium, lead and mercury are ICH Q3D Class 1 elemental impurities. The reference limits are the USP <232> / ICH Q3D permitted daily exposures for parenteral products, converted to a concentration assuming 10 g of product a day (Option 1). A typical peptide dose is a few milligrams, so these limits are very conservative. "Below reference limit" means the measured concentration is under that limit.

Results are stated as the laboratory reported them; Testides sets no limit of its own and draws no conclusion on safety, efficacy, fitness for use, or regulatory status.